目的:通过快速卫生技术评估,评价艾塞那肽的有效性、安全性和经济性,帮助临床医生和决策者更好地了解现有的循证医学证据。方法:系统检索PubMed、Embase、the Cochrane Library、CNKI、万方、SinoMed和HTA相关的网站及数据库。由两名评价者独立地根据纳入和排除标准筛选文章,提取数据,评价文献质量并分析。结果:共纳入1篇HTA报告,6篇系统评价和7篇经济学评价。艾塞那肽与安慰剂相比能够显著降低HbA1c水平,FPG水平和体质量,但是低血糖和胃肠道不良反应发生率较高。与胰岛素相比时,艾塞那肽在降低HbA1c和FPG水平上没有显著差异,但是能够大大减轻体质量。不良反应方面,艾塞那肽的低血糖风险显著低于胰岛素,头痛的发生率与胰岛素没有显著差异,而恶心、呕吐、腹泻的发生率高于胰岛素。结论:艾塞那肽具有良好的有效性和安全性,在我国应用具有良好的经济性。 OBJECTIVE: To evaluate the efficacy, safety and economy of exenatide through rapid health assessment to help clinicians and policymakers better understand existing evidence-based medicine. Methods: We searched PubMed, Embase, the Cochrane Library, CNKI, Wanfang, SinoMed and HTA related websites and databases. Two reviewers independently screened articles based on inclusion and exclusion criteria, extracted data, evaluated the quality of the literature and analyzed. Results: A total of 1 HTA report, 6 systematic reviews and 7 economic evaluations were included. Exenatide significantly reduced HbA1c levels, FPG levels, and body weight compared to placebo, but high rates of hypoglycemia and gastrointestinal adverse events were observed. Exenatide had no significant difference in decreasing HbA1c and FPG levels when compared to insulin, but significantly reduced body mass. In adverse reactions, exenatide significantly lower the risk of hypoglycemia than insulin, the incidence of headache and no significant difference in insulin, and nausea, vomiting, diarrhea, the incidence of insulin. Conclusion: Exenatide has good efficacy and safety, and has good economy in our country.